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OBJECTIVE — The Diabetes Care Protocol (DCP), a multifaceted computerized decision
support diabetes management intervention, reduces cardiovascular risk of type 2 diabetic pa-
tients. We performed a cost-effectiveness analysis of DCP from a Dutch health care perspective.
RESEARCH DESIGN AND METHODS — A cluster randomized trial provided data of
DCP versus usual care. The 1-year follow-up patient data were extrapolated using a modiﬁed
Dutch microsimulation diabetes model, computing individual lifetime health-related costs, and
health effects. Incremental costs and effectiveness (quality-adjusted life-years [QALYs]) were
estimated using multivariate generalized estimating equations to correct for practice-level clus-
tering and confounding. Incremental cost-effectiveness ratios (ICERs) were calculated and cost-
effectiveness acceptability curves were created. Stroke costs were calculated separately.
Subgroupanalysesexaminedpatientswithandwithoutcardiovasculardisease(CVDorCVD
patients, respectively).





costs were reduced (€587, P  0.05).
CONCLUSIONS — DCPreducescardiovascularrisk,resultinginonlyaslightimprovement
in QALYs, lower CVD costs, but higher total costs, with a high cost-effectiveness ratio. Cost-
effective care can be achieved by focusing on cardiovascular risk factors in type 2 diabetic
patients with a history of CVD.
Diabetes Care 33:258–263, 2010
E
very year a large percentage of the
total health care budget is spent on
diabetes-related care. In European
countries percentages of 2.5–6.5% have
been reported, and in the U.S. diabetes-
relatedcostsareevenhigherat10%ofthe
total health care budget (1,2). Long-term
clinical follow-up studies (3–5) have
shown that improvements in glycemic
control, blood pressure, and cholesterol
levels lead to fewer micro- and macrovas-
cular complications and improve health
outcomes. Intensive treatment, based on
current guidelines, might lead to lower
health care costs. However it seems difﬁ-
culttofollowguidelines,andmanytype2
diabetic patients do not meet the strict
targets for good glycemic and cardiovas-
cular control.
New strategies like the Diabetes Care
Protocol (DCP) have been developed to
improve the quality and management of
diabetescare(6).TheDCPcomprisessev-
eral interventions, including a diabetes
consultationhourrunbyapracticenurse,
a computerized decision support system
(CDSS), a recall system, and feedback on
performance. A cluster randomized trial
proved that the DCP reduces the cardio-
vascular risk of type 2 diabetic patients in
primary care (6).
Although it is stated that information
technology, like CDSS, in diabetes care
may improve care processes, delay diabe-
tes complications, and save health care
costs (7), most studies in this ﬁeld do
not include a cost-effectiveness analysis
(8). We therefore performed a cost-
effectiveness analysis of the DCP versus





Between March 2005 and August 2007,
we performed a cluster randomized trial
in 55 primary care practices throughout
the Netherlands. The practices were not
involved in any other diabetes care im-
provement program and worked with an
electronic medical record. Randomiza-
tion was performed at practice level with
stratiﬁcation for the number of primary
care physicians (PCPs) working in the
practice and the presence of a practice
nurse prior to the intervention. Twenty-
six practices were randomized to the in-
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group.
Patients in the intervention group
weretreatedaccordingtotheDCP,which
is described elsewhere (6). In brief, DCP
consistsof1)adiabetesconsultationhour
run by a practice nurse, 2) a CDSS con-
taining a diagnostic and treatment algo-
rithm based on the Dutch primary care of
type2diabetesguidelines(9)andprovid-
ing patient-speciﬁc treatment advice, 3)a
recall system, and 4) feedback at both
practice and patient level every 3 months
regarding the percentage of patients
meeting the treatment targets (smoking
cessation, A1C 7%, systolic blood pres-
sure 140 mmHg, total cholesterol 4.5
mmol/l, LDL cholesterol 2.5 mmol/l,
and BMI 27 kg/m
2) (9). The PCP re-
mained responsible for new prescriptions
and referrals. The control group contin-
ued receiving usual diabetes care, mean-




from the electronic medical records. Pa-
tients under primary care treatment were
eligible. We excluded patients if they
wereunabletovisittheprimarycareprac-
tice, were under specialist treatment, or
had a short life expectancy. The ﬁnal,
mainly Caucasian, study population con-
sisted of 3,391 patients (1,699 interven-
tion group, 1,692 control group). All
patients were seen for their annual diabe-
tes checkup at baseline and after 1 year
follow-up (6).
Lifetime extrapolation of trial results
to costs and effects
Lifetime costs and health effects were es-
timated using a modiﬁed probabilistic di-
abetes model for the Netherlands. This
validatedmodelhasbeenusedbeforeand
is described in more detail elsewhere
(10–12).Inbrief,themodelsimulatesthe
natural history of type 2 diabetes and cal-
culates costs and quality-adjusted life-
years (QALYs) for Dutch type 2 diabetic
patients (12). It accounts for aging, tem-
poral increases in A1C, and the age-
related increase in complication risks.
The model includes a health state for
cardiovascular disease (CVD) (angina
pectoris and myocardial infarction), ma-
jor type 2 diabetes–related complications
(blindness, end-stage renal disease
[ESRD], or lower-extremity amputation),
minor type 2 diabetes complications (ret-
inopathy or diabetic ulcers), uncompli-
cated type 2 diabetes, and death. The
model computes the occurrence of the
above-mentioned diabetes-related com-
plications and the excess mortality due to
diabetes. Based on the estimated events
and prevalence of complications, it com-
putes diabetes-related lifetime medical
costs and QALYs. To calculate lifetime
costs and outcomes, each health state is
assigned a value in terms of medical costs
and utility (health-related quality of life),
and this value is multiplied by the preva-
lence of the health states over time.
Absolute Dutch excess mortality risk
estimates for type 2 diabetes were calcu-
lated by multiplying sex and age-speciﬁc
national mortality rates by the observed
excess mortality hazard ratio for diabetic
patients (10). The computed life-years
wereadjustedbyquality-of-liferesultsfor
major complications (blindness/poor vi-
sion, ESRD, or lower-extremity amputa-
tion),asobservedinearlierDutchstudies,
toderivetheQALYs(10,12–14).TheA1C
levels for individual patients are used to
adjust the baseline risks (transition prob-
abilities) of blindness, renal failure, and
lower-extremity amputation (10,15).
Forthisstudy,threeadaptationswere
made to the original Dutch model. First,
the distribution of the difference in 10-
year UK Prospective Diabetes Study
(UKPDS) coronary heart disease (CHD)
risk estimate between intervention and
control group was used to account for the
differenceintheprobabilityofﬁrstevents
and death from CHD (16). Second, be-
cause patients with a history of CVD have
an even higher increased risk of another
cardiovascular event than diabetic pa-
tients without such a history, a separate
extra risk for this subpopulation was
added to the model. This correction was
based on (W.K.R., L.W.N., unpublished
data)subgroupanalysesoftheoriginalin-
ﬁle Dutch data from the EUROPA trial in
secondary cardiovascular prevention. In
that population, men with diabetes and a
history of CVD showed a risk of a cardio-
vascular death that was 3.27 times that
seeninthegeneralpopulation;inwomen,
this relative risk was 4.63 (17). Finally,
the costs of CHD complications were in-
cluded in the model, based on resource
use observed among Dutch diabetic pa-
tients with the mix of CHD complications
observed in the EUROPA study (17).
In addition to the model input data
described above, medication costs of glu-
cose-loweringdrugs(oraldrugsandinsu-
lin), ACE inhibitors, angiotensin-renin
blockers, and cholesterol-lowering drugs
(ATC codes A10, C09, and C10) used
during the 1-year follow-up period were
included in the cost calculation. The
mean 1-year follow-up medication costs
were €326.30 in the DCP group and
€325.10inthecontrolgroup.Thesecosts
were extrapolated to estimate lifetime
medication costs, assuming the cost dif-
ference between DCP and usual care re-
mained constant over time (Dutch
Farmacotherapeutisch Kompas 2008).
Because differences in use and costs of
diuretics, -blocking agents, and calcium
channel blockers (ATC codes C03, C07,
and C08) between both groups were neg-
ligible, they were left out of the medica-
tion cost calculations.
Costsregardingdevelopmentandim-
plementation of DCP were based on costs
actually invoiced to Pﬁzer B.V.; mainte-
nance costs of DCP were based on costs
invoiced to PCPs. DCP costs were calcu-
lated per patient per year for a period of
10 years based on the CHOICE method
(18). The total DCP costs included prac-
tice nurse instructions working with
DCP, reorganizing primary care practice
type2diabetescare,CDSSwithrecallsys-
tem, and 3-monthly feedback. The costs
of developing the DCP and a pilot study
were divided by the total Dutch type 2
diabetic population, resulting in costs of
€1 per patient. Implementation costs
(ﬁrst 3 years) and the yearly maintenance
costs thereafter were divided by the num-
ber of patients in the participating type 2
diabetic population. Annual implementa-
tioncostswere€90perpatientfortheﬁrst
3 years and annual maintenance costs
were €12 per patient for years 4–10. Be-
cause time spent on diabetes care was not
registered adequately, we performed a
survey among the participating practices
to study if there were extra costs for per-
sonnel, education, and medical equip-
ment(responserate:50%interventionvs.
65% control). Since no differences were
found, these costs were left out of the
model.
Stroke was left out of the model cal-
culations because there are no accurate
Dutch data on survival rates of type 2
diabetic patients with stroke. In the on-
line appendix (available at http://care.
diabetesjournals.org/cgi/content/full/
dc09-1232/DC1), the estimated stroke
costs are calculated.
Analyses
The 1-year follow-up data from the trial
were used, based on intention to treat
with baseline values carried forward in
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the following parameters from the 1-year
follow-up results to calculate lifetime dis-
ease outcomes: age, sex, duration of dia-
betes, A1C, systolic blood pressure, total
cholesterol, HDL cholesterol, BMI, smok-
ing, diabetes complications at 1-year
follow-up (myocardial infarction, an-
gina pectoris, stroke, lower-extremity
amputation, retinopathy [no, back-
ground, or proliferate], neuropathy,
and nephropathy [no, microalbumin-
uria, or macroalbuminuria]).
The model calculated six lifetime
health outcomes (life-years, QALYs) and
costsforeachpatient(discountedandun-
discounted). The averages of the six indi-
vidual model outcomes were then
analyzed using generalized estimating
equations (GEEs) to correct for clustering
at practice level. To correct for confound-
ingandtoimprovemodelestimatesofthe
difference in outcomes between DCP and
control, the following baseline covariates
were used: age, sex, duration of diabetes,
history of CVD, smoking, A1C, systolic
blood pressure, total cholesterol, and
HDL cholesterol.
The primary outcome in our analysis
was the cost-effectiveness of DCP versus
currentusualcare,expressedastheincre-
mental cost-effectiveness ratio (ICER),
calculated by dividing the incremental
costs by the incremental QALYs or incre-
mentallife-years.Asrecommendedbythe
Dutch pharmacoeconomic guidelines,
costs were discounted at 4%, QALYs at
1.5%, and life-years were undiscounted




Uncertainty surrounding the cost-
effectiveness ratios as calculated from the
model was expressed using a cost-
effectiveness plane. A cost-effectiveness
acceptability curve was created to deter-
mine whether implementation of DCP
was cost-effective given different thresh-
oldsofwillingnesstopayforQALYs(e.g.,
a threshold of €20,000 per QALY).
After calculating the mean individual
costs for each patient, we examined the
cost-effectiveness of DCP for all patients
in the study population, patients with a
history of CVD (CVD) and patients
without a history of CVD (CVD).
RESULTS
Trial
The mainly Caucasian study population
had a mean age of 65 years and a mean
diabetes duration of 5.5 years (Table 1).
Baseline characteristics of the two groups
werecomparable,exceptforsmokingsta-
tus, history of CVD, and HDL cholesterol
level. At 1-year follow-up, patients in the
intervention group showed signiﬁcantly
greaterreductionsinbloodpressure,total
cholesterol, and 10-year UKPDS CHD
risk than patients in the control group.




more QALYs (0.037), slightly more life-
years (0.14), and higher costs (€1,415)
than patients in the control group (Table
2). However, none of these differences
were statistically signiﬁcant. In the total
population, patients receiving DCP care
had signiﬁcantly fewer cardiovascular
events than patients receiving usual care
(i.e., 0.11 fewer events). This was also
true for patients without a history of CVD
(CVD) (0.14 fewer events) (Table 2).
The costs of CHD in the DCP group were
signiﬁcantly lower than those in the con-
trol group (total population €517;
CVD patients €433; CVD patients
€721). The ICER for the total popula-
tion was €38,243 per QALY gained (i.e.,
€1,415/0.037), for the CVD patients
€14,814perQALYgained,andforCVD
patients €121,285 per QALY gained.
Figure 1 shows the degree of uncer-
tainty around the differences in costs and
QALYs between the DCP and control
groups for the total population. The per-
centage of dots in the southeast quadrant
(meaning lower costs and improved
health) for these patients is 3%. Con-
versely, the percentage of dots in the
northwest quadrant (where DCP in-
creases costs and reduces health) is 26%.
The cost-effectiveness acceptability
curves (Fig. 2) show that the DCP for
CVD patients is more likely to be cost-
effectiveatanywillingness-to-paythresh-
old than DCP for all patients or DCP for




(n  1,692) Difference in change
between groups*
95% CI difference
between groups* Baseline After 1 year Baseline After 1 year
Age (years) 65.2  11.3 65.0  11.0
Sex (% male) 48.2 49.8
Caucasian (%) 97.7 97.6
Duration of diabetes 5.8  5.7 5.4  5.8
History of CVD (%) 47.1 63.3
Current smoking (%) 22.6 20.7 16.6 15.5 1.1† 0.7–1.7
Clinical outcome
A1C (%) 7.1  1.3 6.9  1.1 7.0  1.1 6.9  1.0 0.07 0.02 to 0.16
Systolic blood pressure (mmHg) 149  22 143  20 149  21 147  20.8 3.3‡ 0.5–6.0
Diastolic blood pressure (mmHg) 83  11 80  11 82  11 82  10.6 2.2‡ 1.0–3.5
Total cholesterol (mmol/l) 5.0  1.0 4.6  0.9 4.9  1.1 4.8  1.1 0.2‡ 0.1–0.3
HDL cholesterol (mmol/l) 1.36  0.36 1.37  0.37 1.32  0.35 1.33  0.36 0.007 0.038 to 0.023
LDL cholesterol (mmol/l) 2.8  0.92 2.5  0.88 2.8  0.95 2.6  0.97 0.15‡ 0.07–0.23
10-year UKPDS CHD risk (%) 22.5  16.5 20.6  15.0 21.7  15.8 21.6  15.6 1.4‡ 0.3–2.6
Data are means  SD unless otherwise indicated. The 10-year UKPDS CHD risk (%) was calculated using date of onset of diabetes (age-duration of diabetes), sex,
ethnicity, smoking, A1C, systolic blood pressure, total cholesterol, and HDL cholesterol. *GEEs to correct for clustering at practice level. †For percentages, the odds
ratio is given. ‡Improvements of intervention group compared with control group signiﬁcant (P  0.05).
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is applied (21), there is a probability of
cost-effectiveness of 59% for CVD pa-
tientsversus30%forallpatientsand24%
for CVD patients (Fig. 2).
CONCLUSIONS — After 1 year, DCP
results in reduced blood pressure, to-
tal cholesterol, and estimated 10-year
UKPDS CHD risk in comparison with
usual care. This resulted in a cost-
effectiveness ratio of €38,243, which is
higher than the often mentioned will-
ingness-to-pay threshold of €20,000/
QALY (21). In the long run, DCP is
more costly and leads to only slightly
more health than current care, although
it does result in signiﬁcantly lower
CHD costs. The cost-effectiveness ratio
for CVD patients is €14,814 and for
CVD patients €121,285. DCP for
CVD patients has the highest proba-
bility of cost-effectiveness (59% at a
willingness-to-pay threshold of
€20,000/QALY) (21).
When considering the 1-year fol-
low-up 10-year UKPDS CHD risk, 20.6%
in the DCP group versus 21.6% in the
controlgroup,weseeasigniﬁcantthough
small relative risk reduction of 5%. Since
DCP was compared with good usual care,
this may explain why the size of improve-
ments in QALYs (0.037) and life-years
(0.14 years) was small. The costs per life-
year gained were much smaller than the
costs per QALY gained (total popula-
tion €10,107; CVD €5,457; CVD
€16,980). Although there were no signif-
icant differences in A1C between the in-
tervention and control group after 1-year
follow-up, the increase in diabetes costs
was mainly caused by an age-related cu-




this study was improved by including
medication and CHD costs. The increase
in diabetes medication costs after 1 year
was, however, assumed to be constant
overthelifetime.Thismighthoweverbea
conservative assumption, because it is
likely that diabetes-related costs and
medication costs will also increase in the
control group when more type 2 diabetic
patients are treated according to current
guidelines and treatment targets, inde-
pendent of the intervention used.
Although we included a large uns-
elected primary care type 2 diabetic pop-
ulation, it is difﬁcult to generalize the
results to other countries and settings. If
DCP were to be applied in populations
with higher mean A1C levels, larger A1C
reductions would probably be obtained
and more costly A1C-related complica-
tions would be prevented; this would im-
prove the cost-effectiveness of DCP.
However, in countries where the diabetic
Figure 1—Scatter-plot showing incremental costs and health (QALYs discounted). The dots
represent different patient populations and are the result of a second-order uncertainty analysis.
Table 2—Costs and effects of DCP compared with usual care
Total population
(n  3,391)
Patients with history of CVD
(n  1,743)








Differences in health, model calculations
Healthy years (QALYs, discounted) 0.037 0.066 to 0.14 0.07 0.051 to 0.19 0.014 0.141 to 0.169
Life-years 0.14 0.12 to 0.40 0.19 0.07 to 0.45 0.10 0.26 to 0.46
Number of cardiovascular events 0.11 0.18 to 0.04 0.08 0.17 to 0.007 0.14 0.25 to 0.036
Differences in costs, model calculations
Diabetes-related (excluding CHD)
(€, discounted) 1,698 187–3,209 1,167 620 to 2,954 2,146 189 to 4,482
CHD (€, discounted) 587 880 to 294 433 847 to 18 721 1,177 to 265
DCP (€, discounted) 316 315–318 314 3,112–316 319 318–320
Total costs (€, discounted) 1,415 130 to 2,961 1,037 891 to 2,967 1,698 692 to 4,089
Cost-effectiveness, model calculations
Total costs per QALY gained 38,243 14,814 121,285
Total costs per life-year gained 10,107 5,457 16,980
Results are corrected for clustering and baseline differences in age, duration of diabetes, sex, smoking, A1C, systolic blood pressure, total cholesterol, HDL
cholesterol, and history of CVD (only total population). *Mean difference between intervention and control group.
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the small improvement in QALYs will
make cost-effectiveness less likely, even
with less costly interventions. The results
are limited by uncertainties in disease
outcome. Although we calculated the av-
erage of six model outcomes per patient,
this will probably not have led to a better
cost-effectiveness estimation. Further, it
is unlikely that the absence of many base-
line values regarding history of CVD had
any substantial effect on the results, since
relatively few patients developed CVD in
1 year. Although stroke costs were not
included in the model, the estimation of
stroke costs did not have a signiﬁcant ef-
fect on the study outcomes (online
appendix).
Comparison with other studies
We observed that the DCP is more cost-
effective for use among patients with a
history of CVD. These patients can be
considered as high-risk patients, just like
type 2 diabetic patients with microalbu-
minuria or high CVD risk estimates, be-
cause they have an increased risk for a
cardiovascularevent.Infact,thiswasalso
shown by the intensive multifactorial in-
tervention in the young high-risk type 2
diabetic population in the Steno-2 Study.
Theyfounda53%reductionincardiovas-
cular events, which proved to be cost-
effective (22).
The baseline values in our trial are in
accordance with a world wide positive
trend in the general therapeutic approach
of type 2 diabetes with increasing per-
centagesofpatientsachievingtheirtargets
for A1C, blood pressure, and lipids (23).
Under these conditions, a potential cost-
effective outcome will be more difﬁcult to
achieve. Unlike blood glucose level, there
is strong evidence that controlling high
bloodpressureandhighcholesterollevels
signiﬁcantlyreducesbothmacro-andmi-
crovascular complications in type 2 dia-
betic patients. Recent trials suggest that
early strict glycemic control is likely to be
beneﬁcial for many patients (24), but set-
ting a glycemic target is deﬁnitely more
difﬁcult in people with existing diabetes-
related complications (25). This implies
thatPCPswillhavetoprovideamoreper-
sonalized kind of diabetes care for differ-
ent kinds of patients (i.e., those with a
short duration of diabetes and those at
high risk). Based on the results of our
study, we think that DCP or comparable
interventions are only useful instruments
if they can identify these different catego-
riesofpatientstofacilitatestructuredper-
sonalized patient review.
In this study we showed that DCP,
consisting of CDSS, a recall system, feed-
back, and case management, improves
clinicaloutcomeinanunselectedprimary
care type 2 diabetic population and re-
sults in lower CVD-related costs but
much higher diabetes-related costs and a
high cost-effectiveness ratio. In the effort
to improve health in a cost-effective man-
ner, PCPs should not simply focus on
A1C percentage but rather on personal-
ized need-differentiated type 2 diabetes
care.
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